Mr. Robins is Adaptive’s President, Chief Executive Officer and Co-founder. He has held executive-level positions in real estate, investing and medical technology, including: Pulte Homes, Connaught Real Estate Finance, and HealthAxis.com. Mr. Robins started his career in banking for companies such as Wasserstein Perella and Bank of America. In 2012, Mr. Robins was a “40 Under 40” Seattle Leaders honoree. In 2015, he and his brother, Harlan Robins, were honored as one of Goldman Sachs 100 Most Intriguing Entrepreneurs of the Year. Mr. Robins was also a finalist for the Ernst & Young 2016 Entrepreneur Of The Year® Award in the Pacific Northwest. While in college and looking for a way to combine his adventuresome spirit with a vast learning opportunity, he spent 100 days in the wilderness with the National Outdoor Leadership School (NOLs) where he gained his open and interactive leadership style along with his strong teamwork mentality. A Cornell University honors graduate with a major in entrepreneurship and business, Mr. Robins obtained his MBA from The Wharton School at the University of Pennsylvania with a major in finance and concentrations in marketing and operations. In addition to the Adaptive Biotechnologies board, Mr. Robins holds board positions for the American Heart Association (Puget Sound) and Pavia Systems. He is also the co-founder and Director of Aortica Corporation, a company that is simplifying endovascular repair (EVAR) for abdominal aortic aneurysms (AAA).
Dr. Robins leads our scientific research and development teams. He is also currently the Computational Biology Program Head at the Fred Hutchinson Cancer Research Center (FHCRC). Dr. Robins’ background in science is remarkable. He obtained his bachelor’s degree at Harvard University as a physics major with a concentration in mathematics. He then obtained his Masters and Ph.D. in theoretical physics (string theory) from the University of California Berkeley with a visiting appointment to the California Institute of Technology (“Caltech”). Dr. Robins obtained a postdoctoral appointment in theoretical physics in the particle theory group at the Weizmann Institute of Science in Israel. Interested in the mathematics behind genetics and observing the potential utility of high-level mathematics to study problems in the biological sciences, Dr. Robins took another postdoctoral appointment at the Institute for Advance Study in Princeton to study under the famed biologist Dr. Arnold Levine. Working with Dr. Levine, Dr. Robins concentrated on developing bioinformatic algorithms for micro RNA targets and bacterial genome analysis, a precursor to his current faculty appointment at the Fred Hutchinson Cancer Research Center in the Computational Biology Group, Public Health Sciences and Human Biology Divisions. In 2009, Dr. Robins was the recipient of the Ellison Award from the Ellison Medical Foundation New Scholars Program to support new investigators of outstanding promise in the basic biological sciences. Dr. Robins was also granted the Keck Foundation Medical Research Award in 2010, along with Dr. Christopher Carlson, to support their work at the FHCRC in advanced DNA sequencing methods to measure past and present pathogenic exposure in humans. Along with Chad Robins, Dr. Robins was most recently recognized as one of Goldman Sachs “100 Most Intriguing Entrepreneurs."
Dr. Miralles heads the Therapeutics Division of Adaptive. Prior to Adaptive, Dr. Miralles was the Global Head, Johnson & Johnson Innovation where he established the Johnson & Johnson Innovation Centers, JLABS, and Janssen Healthcare Innovation. He was also the head of the Janssen Research and Early Development unit in La Jolla, California and founded and launched the JLABS incubator in 2012 for start-up life science entrepreneurs, and was instrumental in developing and launching Johnson & Johnson’s Innovation center model in 2013. While at Tibotec, he was instrumental in the clinical development and regulatory approval of Prezista and Intelence, 2 HIV drugs that helped change the course of HIV infection. Prior to Johnson & Johnson, Dr. Miralles held R&D positions at Trimeris and Triangle Pharmaceuticals and was an Assistant Professor at Duke University Medical Center. He is currently an Adjunct Professor in the Department of Pharmacology at the University of California San Diego. Dr. Miralles received his M.D. degree from the Universidad de Buenos Aires, Argentina and completed his internal medicine residency at the Mayo Clinic, and was a fellow in Infectious Diseases at Cornell University-New York Hospital.
Ms. Rubinstein oversees our global commercial and business development efforts including strategic and financial transactions with corporate, pharma and academic partnerships, as well as clinical sales. Prior to joining Adaptive, Ms. Rubinstein has held various worldwide commercial development roles at Pfizer Oncology, Johnson & Johnson and Morgan Stanley’s Global Health Care Group. She is also the Vice-Chair of the Board for The Valerie Fund, a pediatric oncology organization in New Jersey and New York. Ms. Rubinstein holds an MBA from Harvard Business School.
Mr. Sang oversees the global product strategy and management of our Diagnostics business. He was most recently the Vice President of Global Diagnostics for Nanostring Technologies, Inc. and led their North American and Global commercial efforts for a new product class of decentralized genomic assays in solid and liquid tumors. Mr. Sang has more than 20 years of Hematology/Oncology expertise, including the global launch of products in highly specialized markets while ensuring their reimbursement. He has also held commercial leadership positions at Seattle Genetics and Enzon Pharmaceuticals. Mr. Sang obtained his Master’s degree from New Mexico State University.
As Chief Financial Officer, Mr. Cohen leads our finance and accounting functions as well as oversees our human resources, facilities management and corporate IT services. Prior to Adaptive, he served as the CFO for the Zillow Group where he built the company’s core finance, treasury and accounting functions, and led the finance organization through Zillow’s 2011 IPO and nine acquisitions. In 2013, he was named Puget Sound Business Journal’s CFO of the year. Before Zillow, Mr. Cohen worked for Ticketmaster Entertainment, Countrywide Bank, Ernst & Young and Novellus Systems. Mr. Cohen currently serves as a Board Director at Trupanion (NASDAQ: TRUP). He also served on Adaptive’s board from March 2015 until his appointment as CFO in August 2015. He was also previously a board member for Ticketfly as Audit Chairman until its acquisition by Pandora in 2015. Mr. Cohen graduated from Boston University with a Bachelor of Science in Business Administration and is licensed (inactive) as a CPA in California.
Mr. Nolan oversees software development and architecture, information technology and automation. Prior to Adaptive he has held various healthcare-focused leadership roles with Microsoft’s HealthVault and Health Solutions Group, and was Chief Technology Officer for Drugstore.com. Mr. Nolan was also part of the founding teams that created key advances in healthcare innovation technology including Blue Button and the Direct messaging protocol, both now part of federal standards and regulation.
Ms. Hill leads the operations and marketing functions at Adaptive, including portfolio management, product development, strategic planning, client services, and corporate communications. She is an accomplished global executive with extensive biotechnology, oncology and medical device experience in both development and commercial stages. Prior to Adaptive, Ms. Hill held senior commercial positions with Spiration (a subsidiary of Olympus Corporation), Amgen, Immunex and Berlex Oncology. She earned an MBA from the Kellogg School of Management at Northwestern University.
Dr. Cimler leads our regulatory and quality organization. She has over 26 years of experience in the life science and FDA-regulated and global diagnostic industry leading regulatory, quality systems, clinical affairs, research, and product development organizations. Prior to Adaptive, Dr. Cimler served as Head of Global Quality and Vice President of Quality, Regulatory and Government Affairs at Illumina Inc. resulting in the first next generation sequencing platform (MiSeqDx) to receive FDA marketing authorization. Previously she also held leadership positions in quality, regulatory and government affairs for companies such as Beckman Coulter Inc., Abbott Molecular, Gen-Probe Inc., and C.R. Bard. Dr. Cimler holds a Ph.D. in Pharmacology from the University of Washington.
Eric Dobmeier is Chief Operating Officer of Seattle Genetics. He oversees the company's business development, corporate communications, manufacturing and program/alliance management groups, as well as corporate strategy initiatives. While at Seattle Genetics he has led negotiation and completion of multiple corporate alliances, including the ex-U.S./Canada development and commercialization agreement with Takeda Pharmaceutical Company for ADCETRIS® and ten ADC collaborations with leading biotechnology and pharmaceutical companies. He has also been directly involved in raising more than $1.2 billion in capital for Seattle Genetics. Prior to joining the company, Mr. Dobmeier was with the law firms of Venture Law Group and Heller Ehrman LLP where he represented technology companies in connection with public and private financings, mergers and acquisitions and corporate partnering transactions.
David Goel co-founded Matrix Capital Management, a $2.5 billion long/short public equity fund with a 18-year track record. The fund holds a concentrated portfolio of high conviction, uniquely researched investment ideas, with a focus on technology, media/telecom, consumer, and service industries. Prior to forming Matrix Capital Management in 1999, David was a Member at Tiger Management. Previously, he was an Associate at General Atlantic Partners and a Financial Analyst at Morgan Stanley, focusing on Technology Investment Banking. David is a Director of Univision Communications, Inc., the leading American Spanish broadcasting media company based in New York, NY and he is also a Director of Popular, Inc., a bank with operations in New York, Florida and Puerto Rico. He is a Trustee of Phillips Exeter Academy, the Winsor School of Boston and the Museum of Fine Arts, Boston. David received a Bachelor of Arts (Magna Cum Laude) from Harvard University and is a graduate of Phillips Exeter Academy.
In January of 2016, Dr. Hershberg began serving as the Executive Vice President and Chief Scientific Officer at Celgene in addition to his role as founder and Chief Executive Officer at VentiRx Pharmaceuticals. VentiRx is a clinical stage biopharmaceutical company committed to the development and commercialization of novel medicines for the treatment of cancer. Prior to VentiRx, Dr. Hershberg served as Senior Vice-President and Chief Medical Officer at Dendreon Corporation, developing immunotherapy approaches for cancer. Previously, Dr. Hershberg was an Assistant Professor at Harvard Medical School and an Associate Physician at the Brigham and Women’s Hospital in Boston.
In 1979, Dr. Levine and others discovered the p53 tumor suppressor protein, a molecule that inhibits tumor development. As chair of the National Institutes of Health Commission on AIDS Research and the National Academies Cancer Policy Board, he has helped determine national research priorities. He established the Institute’s Center for Systems Biology, which concentrates on research at the interface of molecular biology and the physical sciences - on genetics and genomics, polymorphisms and molecular aspects of evolution, signal transduction pathways and networks, stress responses, and pharmacogenomics in cancer biology.
Mr. Neupert is an Operating Partner at Health Evolution Partners, a private equity fund. Previously, he was the Corporate Vice-President of the Microsoft Health Solutions Group. There he led a global organization dedicated to developing, marketing, selling and supporting software solutions designed to improve healthcare delivery and to empower individuals to become more engaged and responsible for their own health and wellness. Before Microsoft, Mr. Neupert was president and CEO of drugstore.com Inc. He holds an MBA from the Tuck School of Business at Dartmouth College and a bachelor’s degree from Colorado College.
Mr. Robins is currently Adaptive’s President, Chief Executive Officer and Co-founder. He has held executive-level positions in real estate, investing and medical technology, including: Pulte Homes, Connaught Real Estate Finance, and HealthAxis.com. Mr. Robins started his career in banking for companies such as Wasserstein Perella and Bank of America. In 2012, Mr. Robins was a “40 Under 40” Seattle Leaders honoree. In 2015, he and his brother, Harlan Robins, were honored as one of Goldman Sachs 100 Most Intriguing Entrepreneurs of the Year. Mr. Robins was also a finalist for the Ernst & Young 2016 Entrepreneur Of The Year® Award in the Pacific Northwest. While in college and looking for a way to combine his adventuresome spirit with a vast learning opportunity, he spent 100 days in the wilderness with the National Outdoor Leadership School (NOLs) where he gained his open and interactive leadership style along with his strong teamwork mentality. A Cornell University honors graduate with a major in entrepreneurship and business, Mr. Robins obtained his MBA from The Wharton School at the University of Pennsylvania with a major in finance and concentrations in marketing and operations. In addition to the Adaptive Biotechnologies board, Mr. Robins holds board positions for the American Heart Association (Puget Sound) and Pavia Systems. He is also the co-founder and Director of Aortica Corporation, a company that is simplifying endovascular repair (EVAR) for abdominal aortic aneurysms (AAA).
Dr. John Stuelpnagel co-founded and was Executive Chairman of Ariosa Diagnostics, Inc. until the company was acquired by Roche in 2015. He also served as the Chairman of Sequenta prior to its acquisition by Adaptive Biotechnologies. In 1998 he co-founded Illumina, Inc. and was instrumental in building Illumina into a life sciences industry leader. During his 12 years at Illumina, Dr. Stuelpnagel served as the company’s first CEO and then transitioned into the role of COO. Prior to Illumina, he was a venture capitalist at CW Group. Dr. Stuelpnagel received his B.S. in Biochemistry and his Doctorate in Veterinary Medicine from the University of California, Davis, and holds an M.B.A. from the University of California, Los Angeles.
Dr. Willis previously oversaw the product development and clinical validation of Adaptive’s diagnostic products. He previously served as the CEO and Co-founder of Sequenta, Inc. (acquired by Adaptive in 2015). Prior to Adaptive, Dr. Willis co-founded ParAllele BioScience (acquired by Affymetrix in 2005). He also co-invented Molecular Inversion Probe technology for high throughput genotyping, while at the Stanford Genome Technology Center. Dr. Willis received his Ph.D. in physics from Stanford University.
Dr. Zoltners holds the Nemmers Professorship in Marketing at the Kellogg School of Management at Northwestern University, where he has been a member of the faculty for more than 30 years. Previously, he was a member of the Business School Faculty at the University of Massachusetts and received his PhD from Carnegie-Mellon University. In 1983, Dr. Zoltners co-founded ZS Associates, a global management consulting firm specializing in sales and marketing strategy, operations and execution. Dr. Zoltners was inducted into the Chicago Entrepreneurship Hall of Fame in 2005.